Santen Pharmaceutical.
$11.89
2
-$0.75-5.93% Monday 20:00
Statistiche
In rialzo oggi
12.64
In ribasso oggi
12.46
In rialzo da 52 settimane
12.64
In ribasso da 52 settimane
8.73
Volume
200
Volume medio
85
Cap. di mercato
4.38B
Rapporto P/E
22.63
Rendimento da dividendi
1.93%
Dividendo
0.23
Prossimamente
7
NOV
Guadagni
30
NOV
Pagamento dei dividendi
aumentato
31
MAR 25
Ex dividendo
diminuito
30
SEP 25
Ex dividendo
Stimato
30
NOV 25
Pagamento dei dividendi
Stimato
31
MAR 26
Ex dividendo
Stimato
30
SEP 26
Ex dividendo
Stimato
Dividendi
1.93%Rendimento da dividendi
Crescita a 10 anni
-9.54%
Crescita a 5 anni
-0.6%
Crescita a 3 anni
-5.09%
Crescita a 1 anno
1.52%
Guadagni
7NovAtteso
EPS attesi
0.150913045863
EPS effettivi
N/D
Le persone seguono anche
Questo elenco si basa sulle watchlist delle persone su Stock Events che seguono SNPHF. Non rappresenta una raccomandazione d'investimento.
Concorrenti
Questo elenco è un'analisi basata su recenti eventi di mercato. Non è una raccomandazione di investimento.
Novartis
NVS
Cap. di mercato244.75B
Roche
RHHBY
Cap. di mercato272.83B
Regeneron Pharmaceuticals
REGN
Cap. di mercato130.59B
Bausch Health Companies
BHC
Cap. di mercato2.18B
Abbvie
ABBV
Cap. di mercato346.75B
Johnson & Johnson
JNJ
Cap. di mercato399.26B
Pfizer
PFE
Cap. di mercato164.39B
Alcon
ALC
Cap. di mercato48.18B
Merck
MRK
Cap. di mercato300.25B
Info
Pharmaceuticals: Other
Health Technology
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
Show more...
CEO
Akira Kurokawa
Dipendenti
3744
Paese
JP
ISIN
JP3336000009